Redhill Biopharma
RDHL
37 hedge funds and large institutions have $1.51M invested in Redhill Biopharma in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 10 closing their positions.
600% more call options, than puts
Call options by funds: $14K | Put options by funds: $2K
3% more capital invested
Capital invested by funds: $1.46M → $1.51M (+$44.4K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
8% less funds holding
Funds holding: 40 → 37 (-3)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.23M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$286K |
| 3 |
Renaissance Technologies
New York
|
+$151K |
| 4 |
CAM
Claret Asset Management
Montreal,
Quebec, Canada
|
+$57.6K |
| 5 |
Morgan Stanley
New York
|
+$25.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$171K |
| 2 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$82K |
| 3 |
Millennium Management
New York
|
-$41.1K |
| 4 |
VF
Virtu Financial
New York
|
-$31K |
| 5 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$23.8K |
RDHL Hedge Fund Activity: Q4 2022 in Review
37 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q4 2022, worth a combined $1.51M — up 3% from $1.46M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RDHL and 8 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $3.23M. The largest seller was BlackRock, exiting entirely with an estimated $171K sold.
- 37 institutional investors held Redhill Biopharma (RDHL) as of Q4 2022, down from 40 in Q3 2022.
- Funds reported $1.51M of Redhill Biopharma stock for Q4 2022, up 3% quarter-over-quarter.
- 8 funds opened new Redhill Biopharma positions in Q4 2022 and 10 closed out, a net change of -2 holders.
- The largest Redhill Biopharma buyer in Q4 2022 was Sabby Management, an estimated $3.23M added.
- The largest Redhill Biopharma seller in Q4 2022 was BlackRock, an estimated $171K sold.
Based on aggregated 13F filings for Q4 2022.